Expert Interview
A Second Look: Discussing the potential of Zuranolone(SAGE-217/BIIB125) in patients with major depressive disorder(MDD) and postpartum depression(PPD).
Ticker(s): SAGE.
Institution: Private Practice(Self)
- Special interest in ADHD and became Medical Director of Optax, a start-up marketing the McLean Motion and Attention Test, a combination of a Computerized Performance Test with a motion analysis camera.
- Former Medical Director of the in-patient psychiatry unit at Boston Children's Hospital, and a clinical instructor at Harvard Medical School.
- Transitioned to private practice in 2007, with a very full caseload, with a continued emphasis on the diagnosis and treatment of ADHD through the lifespan, although he treats many patients with a range of other conditions, especially depression and anxiety.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
